A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19

Effective and reliable treatments for SARS-CoV-2 infections are a key part of global COVID-19 management. Based on vitro studies, niclosamide has been considered as a potential drug candidate for SARS-CoV-2, but its clinical development has been limited due to poor solubility and bioavailability. He...

Full description

Saved in:

Bibliographic Details
Published in:	Nature communications Vol. 16; no. 1; pp. 7084 - 9
Main Authors:	Kim, Jung Ho, Kym, Sungmin, Kim, Shin-Woo, Park, Dae Won, Kwon, Ki Tae, Seo, Jun-Won, Yu, Seungjin, Choi, Goeun, N, Sanoj Rejinold, Choy, Jin-Ho, Jin, Geun-woo, Choi, Jun Yong
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01.08.2025 Nature Publishing Group Nature Portfolio
Subjects:	140/131 147/135 147/143 38/77 38/88 631/326/596/4130 692/308/153 692/308/2779/777 692/699/255/2514 Adult Aged Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Bioavailability Clinical trials COVID-19 COVID-19 - virology COVID-19 Drug Treatment COVID-19 vaccines Double-Blind Method Drug development Drug dosages Effectiveness Female Humanities and Social Sciences Humans Male Middle Aged multidisciplinary Niclosamide Niclosamide - administration & dosage Niclosamide - adverse effects Niclosamide - therapeutic use Pandemics Patients Pharmacokinetics Placebos SARS-CoV-2 - drug effects Science Science (multidisciplinary) Severe acute respiratory syndrome coronavirus 2 Treatment Outcome Viral diseases Viral Load - drug effects
ISSN:	2041-1723, 2041-1723
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!